Amgen closes 2025 with record revenues of $36.8 billion, driven by double-digit volume growth. Looking ahead to 2026, the biotech giant focuses on the global commercialization of Imdelltra and high-stakes data readouts for its obesity candidate, MariTide.
Eli Lilly (LLY) shattered Q4 2025 expectations with $19.3 billion in revenue, marking a 43% year-over-year increase. Driven by the explosive demand for weight-loss treatments Mounjaro and Zepbound, the pharmaceutical giant issued a confident 2026 revenue guidance of $80B–$83B, signaling continued dominance in the metabolic health market.
Eli Lilly and Company has announced a historic $3.5 billion investment to establish a state-of-the-art manufacturing campus in Fogelsville, Pennsylvania. As the largest life sciences project in the Commonwealth’s history, this facility will be dedicated to producing next-generation injectable medicines, including the investigational triple hormone receptor agonist retatrutide. The project is set to create 850 high-value jobs and solidify the Lehigh Valley as a premier global hub for pharmaceutical innovation and domestic supply chain resilience.
Roche has announced robust 2025 results, reporting a 7% increase in Group sales (CER) and a massive 58% jump in IFRS net income. With 12 positive late-stage clinical readouts—including the promising obesity candidate CT-388—and a bullish 2026 forecast, the Swiss healthcare giant proves its resilience despite significant currency headwinds.
Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), has reported record-breaking financial results for the fourth quarter and full fiscal year [Read More…]
Abbott concludes 2025 with double-digit earnings growth and a powerful surge in Medical Device sales. With a new 2026 organic growth forecast of 6.5%–7.5% and a major entry into cancer diagnostics via the Exact Sciences acquisition, the healthcare leader signals a year of accelerated expansion ahead.
ohnson & Johnson has concluded a ‘catapult year’ with $94.2 billion in revenue, driven by a surge in oncology sales and strategic MedTech innovations. As the healthcare giant prepares to spin off its orthopaedics business, it sets its sights on becoming the first healthcare company to surpass the $100 billion annual revenue milestone in 2026.
In a major shift for the pharmaceutical industry, AbbVie (NYSE: ABBV) announced on Monday a sweeping, voluntary agreement with the Trump administration designed to lower [Read More…]
In a move that signals a significant shift in the relationship between Big Pharma and the federal government, Johnson & Johnson (NYSE: JNJ) announced a [Read More…]
Eli Lilly expands its clinical-stage portfolio with the $1.2 billion acquisition of Ventyx Biosciences, securing high-potential oral NLRP3 inhibitors to treat chronic inflammation and neurodegenerative disorders.
